TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.

JAK3:1.2 nM, CLK2:<2.0 nM, YES1:<2.0 nM, FGR:<2.0 nM, c-Src:1.3 nM

A large set of kinase assays showed that TAK-901 inhibited multiple kinases (including FLT3, FGFR and Src family kinases) with IC50 values similar to those of Aurora A and B. TAK-901 inhibited Aurora A-TPX2 and Aurora B-INCENP in a tightly bound manner in a time-dependent manner.TAK-901 inhibited Aurora A-TPX2 and Aurora B-INCENP in a time-dependent manner. TAK-901 inhibited the NFkB and JAK/STAT pathways with submicromolar potency in a panel of pathway-specific reporter gene-based cell models.TAK-901 inhibited cell proliferation in human tumor cell lines from various tissues with IC50s ranging from 40 to 500 nM.TAK-901 inhibited the proliferation of human PC3 prostate cancer and HL60 acute myeloid leukemia cells in human PC3 prostate cancer and HL60 acute myeloid leukemia cells as determined by immunofluorescence and flow cytometry. Myeloid leukemia cells, consistent with Aurora B inhibition.TAK-901 inhibited Flt3 and FGFR2 autophosphorylation in cells with IC50 values close to those of Aurora B as measured by intracellular histidine H3 phosphorylation, whereas the IC50s for inhibition of intracellular Src and Bcr Abl were 20-fold weaker.